The efficacy of antioxidant treatment with mexidol forte in 250 patients with chronic cerebral venous insufficiency

Chukanova, E I; Chukanova, A. S.; Mamaeva, Kh.I. Mamaeva

doi:10.17116/jnevro202112103157

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic cerebral circulatory insufficiency (CCCI) is a common disease in clinical neurology department. It refers to the various causes of cerebrovascular stenosis and (or) low perfusion, reduce the supply of blood flow to the brain tissue, unable to meet the demand of normal brain tissue, on the basis of whole brain blood flow and low metabolism form is given priority to with local pathological changes, causing mild, volatility of brain dysfunction (Chukanova et al., 2021 ). The main clinical symptoms were memory deterioration, insomnia, vertigo, headache, cognitive decline, etc., which could be confirmed by brain CT and MRI scans, and the patients did not have vascular or organic brain lesions (Ding et al., 2019 ).…”

Section: Introductionmentioning

confidence: 99%

“…In recent years, butylphthalide and urinary kallidinogenase treatment for ischemic stroke has been considered as a promising strategy in China. They have the ability to improve cerebral blood flow reserve, promote collateral circulation, protect neurons, and improve the prognosis of patients with ischemic cerebrovascular diseases (Chen et al., 2019 ; Ni et al., 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical efficacy analysis of butylphthalide combined with urinary kallidinogenase in treating chronic cerebral circulatory insufficiency

Qiao

2023

Brain and Behavior

View full text Add to dashboard Cite

Objective To investigate the clinical effect of butylphthalide combined with urinary kallidinogenase in the treatment of chronic cerebral circulatory insufficiency (CCCI). Methods A total of 102 CCCI patients admitted to our hospital from October 2020 to December 2021 were retrospectively enrolled in this study. According to the different therapeutic strategy, the patients were divided into combined group (treated with butylphthalide combined with urinary kallidinogenase, n = 51) and butylphthalide group (treated with butylphthalide, n = 51). Blood flow velocity and cerebral blood flow perfusion before and after treatment between the two groups were compared. The clinical efficacy and adverse events of the two groups were analyzed. Results After treatment, the effective rate of the combined group was significantly higher than the butylphthalide group ( p = .015). Before treatment, the blood flow velocity of middle cerebral artery (MCA), vertebral artery (VA), basilar artery (BA) were comparable ( p > .05, respectively), while after treatment, the blood flow velocity of MCA, VA, and BA in combined group were faster than those in butylphthalide group ( p < .001, respectively). Before treatment, the relative cerebral blood flow (rCBF), relative cerebral blood volume (rCBV), relative mean transmit time (rMTT) of the two groups were comparable ( p > .05, respectively). After treatment, rCBF and rCBV in combined group were higher than those in butylphthalide group ( p < .001, respectively), and rMTT in combined group was lower than that in butylphthalide group ( p = .001). The rate of adverse events in the two groups were comparable ( p = .558). Conclusion Butylphthalide combined with urinary kallidinogenase can improve the clinical symptoms of CCCI patients, and the effect is promising, which is worthy of clinical application.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%